{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:08Z","timestamp":1786992008450,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jdiacomp.2020.107619","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:16:19Z","timestamp":1589152579000},"page":"107619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Weight-centric pharmacological management of type 2 diabetes mellitus \u2013 An essential component of cardiovascular disease prevention"],"prefix":"10.1016","volume":"34","author":[{"given":"Emir","family":"Muzurovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini\u0161a","family":"Dragni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Medenica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigita","family":"Smolovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Bulaji\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri P.","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107619_bb0005","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","article-title":"Epidemiology of obesity and diabetes and their cardiovascular complications","volume":"118","author":"Bhupathiraju","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0010","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"4","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pcad.2013.10.016","article-title":"Overview of epidemiology and contribution of obesity to cardiovascular disease","volume":"56","author":"Bastien","year":"2014","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0020","article-title":"Associations between BMI, waist circumference, central obesity and outcomes in type II diabetes mellitus: the ACCORD trial","volume":"107499","author":"German","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14656566.2018.1428558","article-title":"Pharmacotherapy for obesity in individuals with type 2 diabetes","volume":"19","author":"Chukir","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0030","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0035","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guide-line for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment","volume":"15","author":"Landsberg","year":"2012","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0045","doi-asserted-by":"crossref","first-page":"432","DOI":"10.2174\/1570161114666160722112738","article-title":"Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?","volume":"14","author":"Katsiki","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017executive summary","volume":"22","author":"Garber","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/dmrr.2517","article-title":"Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk","volume":"30","author":"Soare","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0060","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0065","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14656566.2017.1351946","article-title":"Cardiovascular disease prevention strategies for type 2 diabetes mellitus","volume":"18","author":"Katsiki","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0070","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0003319718776528","article-title":"Abnormal Peri-organ or intra-organ fat deposition and vascular risk","volume":"69","author":"Katsiki","year":"2018","journal-title":"Angiology."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"Obesity management task force of the European Association for the Study of Obesity. European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0080","series-title":"A Practical Guide to Drug-Induced Weight Gain","first-page":"77","author":"Aronne","year":"2002"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0090","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/diacare.25.7.1142","article-title":"A prospective study of obesity and risk of coronary heart disease among diabetic women","volume":"25","author":"Cho","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0095","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0100","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc12-1391","article-title":"Determinants of weight gain in the action to control cardiovascular risk in diabetes trial","volume":"36","author":"Fonseca","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.amjcard.2018.11.016","article-title":"Body mass index, change in weight, body weight variability and outcomes in type 2 diabetes mellitus (from the ACCORD trial)","volume":"123","author":"Yeboah","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/oxfordjournals.aje.a009843","article-title":"Prospective study of intentional weight loss and mortality in overweight white men aged 40\u201364 years","volume":"149","author":"Williamson","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1464-5491.1990.tb01375.x","article-title":"Obesity, weight loss and prognosis in type 2 diabetes","volume":"7","author":"Lean","year":"1990","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0120","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2337\/diacare.23.10.1499","article-title":"Intentional weight loss and mortality among overweight individuals with diabetes","volume":"23","author":"Williamson","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0125","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2337\/diacare.23.10.1451","article-title":"Weight loss and mortality in type 2 diabetes","volume":"23","author":"Pi-Sunyer","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2337\/diacare.27.3.657","article-title":"Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes","volume":"27","author":"Gregg","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/diaspect.20.3.133","article-title":"The dilemma of weight loss in diabetes","volume":"20","author":"Franz","year":"2007","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(19)30425-5","article-title":"Association of insulin resistance and \u03b2-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0150","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus","volume":"170","author":"The Look AHEAD Research Group","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"The Look AHEAD Research Group","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0160","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial","volume":"4","author":"The Look AHEAD Research Group","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0165","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial","volume":"30","author":"The Look AHEAD Research Group","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13668-014-0099-x","article-title":"The Look AHEAD trial: a review and discussion of its outcomes","volume":"3","author":"Pi-Sunyer","year":"2014","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","article-title":"Metformin and body weight","volume":"32","author":"Golay","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/diacare.19.9.920","article-title":"The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group","volume":"19","author":"Fontbonne","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2362.1998.00304.x","article-title":"Effect of metformin on food intake in obese subjects","volume":"28","author":"Paolisso","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207947","article-title":"Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly \u2013 a meta-analysis","volume":"13","author":"Solym\u00e1r","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0225","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug naive patients with type 2 diabetes: a randomized, double-blind, placebo controlled, and parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0230","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus","volume":"28","author":"De Fronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0235","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0240","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0245","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1463-1326.2006.00602.x","article-title":"Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes","volume":"8","author":"Blonde","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0250","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0255","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0260","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0270","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0275","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0285","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0290","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/dom.12660","article-title":"Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment","volume":"18","author":"Umpierrez","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0300","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou","year":"2019","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0310","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomized, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0320","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0325","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0330","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0335","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0340","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomized, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0345","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomized, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0350","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomized controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0355","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0360","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0370","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomized placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0375","article-title":"Tanzeum (albiglutide) discontinued - FDA warns: anaphylaxis reaction [internet]","author":"Warning","year":"2020","journal-title":"TruLaw."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0380","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.3390\/ijms20174092","article-title":"The effects of dual GLP-1\/GIP receptor agonism on glucagon secretion - a review","volume":"20","author":"Mathiesen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0385","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2018-00117","article-title":"Targeting the incretin\/glucagon system with triagonists to treat diabetes","volume":"39","author":"Capozzi","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0390","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0395","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: systematic review and meta-analysis","volume":"29","author":"Monami","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0415","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0420","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0425","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0430","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","article-title":"Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes","volume":"58","author":"Cefalu","year":"2015","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0435","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0440","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence","volume":"96","author":"Katsiki","year":"2019","journal-title":"Metabolism."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0445","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0450","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0455","first-page":"736","article-title":"Ertugliflozin (steglatro): a new option for SGLT2 inhibition","volume":"43","author":"Kovacich","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0460","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12888","article-title":"Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone","volume":"19","author":"Terra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0465","first-page":"1","article-title":"Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study","author":"Aronson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0470","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0475","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0480","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12428","article-title":"Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes","volume":"17","author":"Bode","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLOS ONE."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0490","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007165","article-title":"Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis","volume":"7","author":"Zhang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0495","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1507\/endocrj.EJ17-0372","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis","volume":"65","author":"Li","year":"2018","journal-title":"Endocr J"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425255.2018.1541348","article-title":"SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids","author":"Filippas-Ntekouan","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0505","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/157016111796642661","article-title":"\u201cEuropean panel on low density lipoprotein (LDL) subclasses\u201d: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses","volume":"9","author":"Mikhailidis","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0510","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2174\/157016111796642698","article-title":"\u201cEuropean panel on low density lipoprotein (LDL) subclasses\u201d: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary","volume":"9","author":"Mikhailidis","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0515","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0520","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and type 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0525","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"3","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0530","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0535","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/obr.12318","article-title":"Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Aldekhail","year":"2015","journal-title":"Obesity Revs"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0540","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0545","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0550","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study","volume":"56","author":"Broom","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0555","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phrs.2017.05.022","article-title":"Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials","volume":"122","author":"Sahebkar","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0560","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","journal-title":"Obesity."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0565","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0570","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/fca.15.79","article-title":"Naltrexone\/bupropion for the treatment of obesity and obesity with type 2 diabetes","volume":"12","author":"Apovian","year":"2016","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0575","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0580","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3803\/EnM.2014.29.4.410","article-title":"Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management","volume":"29","author":"Jeon","year":"2014","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0585","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0590","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2010","journal-title":"Obesity."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0595","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0600","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0605","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0610","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0615","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0620","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0625","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic Oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2018","journal-title":"Obesity."},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0630","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1139\/cjpp-2018-0123","article-title":"Effect of a nonsystemic, orally administered hydrogel, GS100, on metformin pharmacokinetics","volume":"96","author":"Urban","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0635","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0640","doi-asserted-by":"crossref","DOI":"10.15344\/2456-8007\/2019\/131","article-title":"Cardiovascular risk reduction associated with pharmacological weight loss: a meta-analysis","volume":"4","author":"Kane","year":"2019","journal-title":"Int J Clin Res Trials"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2637418","article-title":"Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue","volume":"2018","author":"Dias","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107619_bb0650","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jacc.2017.12.014","article-title":"Metabolic surgery","volume":"71","author":"Pareek","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720303755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720303755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:09:56Z","timestamp":1761005396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872720303755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":123,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1056872720303755"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107619","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight-centric pharmacological management of type 2 diabetes mellitus \u2013 An essential component of cardiovascular disease prevention","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107619"}}